血液系统恶性肿瘤中嵌合抗原受体(CAR)-T细胞疗法相关凝血功能异常的研究进展
Research Progress on Coagulation Abnormalities Associated with CAR-T Cell Therapy in Hematological Malignancies
DOI: 10.12677/acm.2025.15102749, PDF,    国家自然科学基金支持
作者: 眭丹丹：赣南医科大学第一临床医学院，江西 赣州；陈懿建*：赣南医科大学第一附属医院血液内科，江西 赣州
关键词: 嵌合抗原受体(CAR)-T细胞疗法；血液系统恶性肿瘤；凝血功能异常；病理生理机制；治疗策略；Chimeric Antigen Receptor T-Cell Therapy； Hematological Malignancies； Coagulation Abnormalities； Pathophysiological Mechanisms； Treatment Strategies
摘要: 嵌合抗原受体(CAR)-T细胞疗法在血液系统恶性肿瘤治疗中显示出显著效果，但伴随严重的毒副作用，其相关凝血功能异常并发症发生率高，可能进展为危及生命的情况，严重影响患者的治疗效果和生存质量。CAR-T细胞疗法相关凝血功能异常的机制涉及炎症反应、血管内皮损伤、肝功能受损及血小板减少等，需通过早期监测和个体化管理策略来改善患者预后。本文旨在综述CAR-T细胞疗法导致凝血异常的临床表现、潜在机制及其处理策略，以期为临床实践提供有价值的参考，帮助医务人员更好地应对这一挑战，优化患者的治疗方案。
Abstract: Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in the treatment of hematological malignancies. However, it is also associated with severe adverse events, particularly a high incidence of coagulation abnormalities, which may progress to life-threatening conditions. These complications significantly impact treatment outcomes and quality of life for patients. The mechanisms underlying CAR-T–related coagulopathy involve inflammatory responses, vascular endothelial injury, liver dysfunction, and thrombocytopenia. Early monitoring and individualized management strategies are needed to improve patient prognosis. This review aims to summarize the clinical manifestations, underlying mechanisms, and management strategies of coagulation abnormalities associated with CAR-T therapy, providing valuable references for clinical practice and helping medical staff better address this challenge and optimize patient treatment plans.
文章引用：眭丹丹, 陈懿建. 血液系统恶性肿瘤中嵌合抗原受体(CAR)-T细胞疗法相关凝血功能异常的研究进展[J]. 临床医学进展, 2025, 15(10): 228-236. https://doi.org/10.12677/acm.2025.15102749

参考文献

[1] Sterner, R.C. and Sterner, R.M. (2021) CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer Journal, 11, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[2] Brudno, J.N. and Kochenderfer, J.N. (2024) Current Understanding and Management of CAR T Cell-Associated Toxicities. Nature Reviews Clinical Oncology, 21, 501-521. [Google Scholar] [CrossRef] [PubMed]
[3] Peng, X., Zhang, X., Zhao, M., Chang, D., Yang, L., Mei, H., et al. (2024) Coagulation Abnormalities Associated with CAR-T-Cell Therapy in Haematological Malignancies: A Review. British Journal of Haematology, 205, 420-428. [Google Scholar] [CrossRef] [PubMed]
[4] Mei, H., Chen, F., Han, Y., Hou, M., Huang, H., Huang, X., et al. (2022) Chinese Expert Consensus on the Management of Chimeric Antigen Receptor T Cell Therapy-Associated Coagulopathy. Chinese Medical Journal, 135, 1639-1641. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, R., Lv, Y., Hong, F., Zhao, W., Lei, B., Liu, J., et al. (2023) A Comprehensive Analysis of Coagulopathy during Anti‐B Cell Maturation Antigen Chimeric Antigen Receptor‐t Therapy in Multiple Myeloma, a Retrospective Study Based on LEGEND‐2. Hematological Oncology, 41, 704-717. [Google Scholar] [CrossRef] [PubMed]
[6] Arai, Y. (2022) Coagulopathy Related to CAR-T Cell Therapy. Rinsho Ketsueki, 63, 1205-1211.
[7] Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., et al. (2019) Improving the Safety of CAR-T Cell Therapy by Controlling Crs-Related Coagulopathy. Annals of Hematology, 98, 1721-1732. [Google Scholar] [CrossRef] [PubMed]
[8] Yamasaki-Morita, M., Arai, Y., Ishihara, T., Onishi, T., Shimo, H., Nakanishi, K., et al. (2022) Relative Hypercoagulation Induced by Suppressed Fibrinolysis after Tisagenlecleucel Infusion in Malignant Lymphoma. Blood Advances, 6, 4216-4223. [Google Scholar] [CrossRef] [PubMed]
[9] Jess, J., Yates, B., Dulau-Florea, A., Parker, K., Inglefield, J., Lichtenstein, D., et al. (2023) CD22 CAR T-Cell Associated Hematologic Toxicities, Endothelial Activation and Relationship to Neurotoxicity. Journal for ImmunoTherapy of Cancer, 11, e005898. [Google Scholar] [CrossRef] [PubMed]
[10] Bindal, P., Patell, R., Chiasakul, T., Lauw, M.N., Ko, A., Wang, T., et al. (2024) A Meta-Analysis to Assess the Risk of Bleeding and Thrombosis Following Chimeric Antigen Receptor T-Cell Therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. Journal of Thrombosis and Haemostasis, 22, 2071-2080. [Google Scholar] [CrossRef] [PubMed]
[11] Schorr, C., Forindez, J., Espinoza-Gutarra, M., Mehta, R., Grover, N. and Perna, F. (2023) Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies. International Journal of Molecular Sciences, 24, Article No. 8349. [Google Scholar] [CrossRef] [PubMed]
[12] Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., et al. (2021) Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T-Cell Therapy. Blood Advances, 5, 4465-4475. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., et al. (2020) Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 26, 865-875. [Google Scholar] [CrossRef] [PubMed]
[14] Song, Z., Tu, D., Tang, G., Liu, N., Tai, Z., Yang, J., et al. (2023) Hemophagocytic Lymphohistiocytosis and Disseminated Intravascular Coagulation Are Underestimated, but Fatal Adverse Events in Chimeric Antigen Receptor T-Cell Therapy. Haematologica, 108, 2067-2079. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, J. and Doran, J. (2021) The Many Faces of Cytokine Release Syndrome-Related Coagulopathy. Clinical Hematology International, 3, 3-12. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, Y., Peng, H., Wang, J. and Li, F. (2024) New Insights into CAR T-Cell Hematological Toxicities: Manifestations, Mechanisms, and Effective Management Strategies. Experimental Hematology & Oncology, 13, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[17] Dong, R., Wang, Y., Lin, Y., Sun, X., Xing, C., Zhang, Y., et al. (2022) The Correlation Factors and Prognostic Significance of Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Cohort Study. Annals of Translational Medicine, 10, 975-975. [Google Scholar] [CrossRef] [PubMed]
[18] Perna, F., Parekh, S., Diorio, C., Smith, M., Subklewe, M., Mehta, R., et al. (2024) CAR T-Cell Toxicities: From Bedside to Bench, How Novel Toxicities Inform Laboratory Investigations. Blood Advances, 8, 4348-4358. [Google Scholar] [CrossRef] [PubMed]
[19] Iba, T. and Levy, J.H. (2018) Inflammation and Thrombosis: Roles of Neutrophils, Platelets and Endothelial Cells and Their Interactions in Thrombus Formation during Sepsis. Journal of Thrombosis and Haemostasis, 16, 231-241. [Google Scholar] [CrossRef] [PubMed]
[20] Hay, K.A., Hanafi, L., Li, D., Gust, J., Liles, W.C., Wurfel, M.M., et al. (2017) Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy. Blood, 130, 2295-2306. [Google Scholar] [CrossRef] [PubMed]
[21] Mackall, C.L. and Miklos, D.B. (2017) CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity. Cancer Discovery, 7, 1371-1373. [Google Scholar] [CrossRef] [PubMed]
[22] Gust, J., Hay, K.A., Hanafi, L., Li, D., Myerson, D., Gonzalez-Cuyar, L.F., et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery, 7, 1404-1419. [Google Scholar] [CrossRef] [PubMed]
[23] Jing, H., Zuo, N., Novakovic, V.A. and Shi, J. (2022) The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients with Cancer and Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 9, Article ID: 792335. [Google Scholar] [CrossRef] [PubMed]
[24] Shafaghat, Z., Ghomi, A.K., Khorramdelazad, H. and Safari, E. (2023) Purinergic Signaling: Decoding Its Role in COVID-19 Pathogenesis and Promising Treatment Strategies. Inflammopharmacology, 31, 3005-3020. [Google Scholar] [CrossRef] [PubMed]
[25] Higuchi, Y., Kubota, T., Koyanagi, M., Maeda, T., Feldman, A.M. and Makino, N. (2012) Upregulation of Anticoagulant Proteins, Protein S and Tissue Factor Pathway Inhibitor, in the Mouse Myocardium with Cardio-Specific TNF-α Overexpression. American Journal of Physiology-Heart and Circulatory Physiology, 302, H2352-H2362. [Google Scholar] [CrossRef] [PubMed]
[26] Wojtukiewicz, M.Z., Mysliwiec, M., Matuszewska, E., Sulkowski, S., Zimnoch, L., Politynska, B., et al. (2021) Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. Biomolecules, 11, Article No. 663. [Google Scholar] [CrossRef] [PubMed]
[27] Wu, Z., Liu, M., Liang, M. and Fu, J. (2012) Sirt1 Protects against Thrombomodulin Down-Regulation and Lung Coagulation after Particulate Matter Exposure. Blood, 119, 2422-2429. [Google Scholar] [CrossRef] [PubMed]
[28] Perl, M., Herfeld, K., Harrer, D.C., Höpting, M., Schweiger, M., Sterz, U., et al. (2024) Tocilizumab Administration in Cytokine Release Syndrome Is Associated with Hypofibrinogenemia after Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. Haematologica, 109, 2969-2977. [Google Scholar] [CrossRef] [PubMed]
[29] Xia, Y., Tang, L. and Hu, Y. (2023) The Risk Factors for Coagulation Disorder of Chimeric Antigen Receptor-T Cell Therapy in Patients with Hematological Tumors: A Systematic Review and Meta-Analysis. Technology and Health Care, 31, 2363-2380. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, X., Li, C., Luo, W., Zhang, Y., Huang, Z., Xu, J., et al. (2023) IL-10 plus the EASIX Score Predict Bleeding Events after Anti-Cd19 CAR T-Cell Therapy. Annals of Hematology, 102, 3575-3585. [Google Scholar] [CrossRef] [PubMed]
[31] Liang, E.C., Huang, J.J., Portuguese, A.J., Ortiz-Maldonado, V., Albittar, A., Wuliji, N., et al. (2025) Development and Validation of Predictive Models of Early Immune Effector Cell-Associated Hematotoxicity. Blood Advances, 9, 606-616. [Google Scholar] [CrossRef] [PubMed]
[32] Li, Z., Que, Y., Wang, D., Lu, J., Li, C., Xu, M., et al. (2023) Recovery-Model: A Model for CAR T-Cell-Related Thrombocytopenia in Relapsed/refractory Multiple Myeloma. Thrombosis Research, 227, 62-70. [Google Scholar] [CrossRef] [PubMed]
[33] Ponnapalli, A., Arora, A.K. and Soubani, A.O. (2025) Critical Care Considerations of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Respiratory Medicine, 238, Article ID: 107958. [Google Scholar] [CrossRef] [PubMed]
[34] Shao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., et al. (2021) CRS-Related Coagulopathy in BCMA Targeted CAR-T Therapy: A Retrospective Analysis in a Phase I/II Clinical Trial. Bone Marrow Transplantation, 56, 1642-1650. [Google Scholar] [CrossRef] [PubMed]
[35] Hu, K., Huang, Y., Hu, Y. and Huang, H. (2022) Progress on CAR-T Cell Therapy for Hematological Malignancies. Journal of Zhejiang University (Medical Sciences), 51, 192-203. [Google Scholar] [CrossRef] [PubMed]
[36] Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M.S., et al. (2022) Recent Findings on Chimeric Antigen Receptor (CAR)-Engineered Immune Cell Therapy in Solid Tumors and Hematological Malignancies. Stem Cell Research & Therapy, 13, Article No. 482. [Google Scholar] [CrossRef] [PubMed]
[37] Su, M., Zhang, Z., Jiang, P., Wang, X., Tong, X. and Wu, G. (2024) CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies. Cell Transplantation, 33, 1-11. [Google Scholar] [CrossRef] [PubMed]

为你推荐